drugset

drugset / Trial / NCT01576575

Buprenorphine Disposition and CYP3A

NCT01576575 ↗

Completed 21 enrolled Washington University School of Medicine

SequentialOpen-labelOther

Summary

To evaluate role of CYP3A in buprenorphine disposition and effect

Timeline

Start: 2010-06
Primary completion: 2014-03-29
Completion: 2014-03-29

Publications

Background Heel RC, Brogden RN, Speight TM, Avery GS. Buprenorphine: a review of its pharmacological properties and therapeutic efficacy. Drugs. 1979 Feb;17(2):81-110. doi: 10.2165/00003495-197917020-00001.
Background Pickworth WB, Johnson RE, Holicky BA, Cone EJ. Subjective and physiologic effects of intravenous buprenorphine in humans. Clin Pharmacol Ther. 1993 May;53(5):570-6. doi: 10.1038/clpt.1993.72.
Background Walsh SL, Preston KL, Bigelow GE, Stitzer ML. Acute administration of buprenorphine in humans: partial agonist and blockade effects. J Pharmacol Exp Ther. 1995 Jul;274(1):361-72.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Buprenorphine	Other / unclassified	0.025 mg	Intravenous
Subject	Buprenorphine	Other / unclassified	0.2 mg	Intravenous
Subject	Buprenorphine	Other / unclassified	2 mg	Intravenous
Subject	Buprenorphine	Other / unclassified	4 mg	Intravenous
Subject	Ketoconazole	Small molecule	400 mg	—
Subject	Rifampin	Small molecule	600 mg	—

Indications

No indication recorded.